# A Pilot Study of the Use of Risperidone Long Acting Injectable in the Treatment of Patients With Recent Onset Psychosis

> **NCT00216580** · PHASE3 · COMPLETED · sponsor: **Janssen Pharmaceutica N.V., Belgium** · enrollment: 50 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Risperidone, long-acting injectable

## Key facts

- **NCT ID:** NCT00216580
- **Lead sponsor:** Janssen Pharmaceutica N.V., Belgium
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-02
- **Primary completion:** —
- **Final completion:** 2006-12
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2013-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00216580

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00216580, "A Pilot Study of the Use of Risperidone Long Acting Injectable in the Treatment of Patients With Recent Onset Psychosis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00216580. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*